# US 2004/0203072 A1 · Uncoupled collagen synthesis and degradation assays

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0203072 A1
- Document ID: US20040203072A1
- Status: Published application
- Kind: A1
- Application number: 10/705,124
- Filed: 2003-11-10
- Published: 2004-10-14
- Earliest claimed: 2002-11-08
- Assignees: Barnes-Jewish Hospital
- Inventors: Linda J. Sandell; Patrick Garnero
- Web page: https://patentgrep.com/patent/US20040203072A1

## CPC

- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- G01N 33/6887: {from muscle, cartilage or connective tissue}
- G01N 2800/10: Musculoskeletal or connective tissue disorders
- G01N 2800/102: Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
- G01N 2800/105: Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
- Y10S 436/811: Test for named disease, body condition or organ function
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The invention relates to methods for determining the progression of cartilage degeneration diseases, such as osteoarthrits and rheumatoid arthritis, by quantitating collagen synthesis and degradation markers in patient samples. One can determine whether a cartilage degeneration condition is progressing, regressing, or remaining stable by quantitating collagen synthesis and degradation markers in patient samples and comparing the value obtained to a reference value. When a joint affected by cartilage degeneration in question expresses collagen synthesis and degradation markers, a change in this value is indicative of a change in the progression of the cartilage degeneration condition. The methods and apparatus of the invention allow accurate determination of the therapeutic effects certain cartilage degeneration drug treatments, including osteoarthritis and rheumatoid arthritis drug treatments, so are also useful for pharmaceutical efficacy studies in mammals.

## Claims

### Claim 1

A method for detecting or predicting cartilage destruction in a subject, said method comprising detecting an uncoupling of type II collagen synthesis from type II collagen degradation in the subject.

### Claim 2 (depends on 1)

A method in accordance with claim 1 wherein detecting an uncoupling of type II collagen synthesis from type II collagen degradation in the subject comprises:
(a) detecting both a synthesis marker and degradation marker in a biological sample of the subject;
(b) comparing the amounts of the synthesis marker and degradation marker; and
(c) correlating the relative amounts of the synthesis marker and degradation marker with predetermined standards to detect cartilage destruction in the subject.

### Claim 3 (depends on 2)

The method of claim 2, wherein step (b) is performed at least twice.

### Claim 4 (depends on 2)

The method of claim 2, wherein step (a) is a single step.

### Claim 5 (depends on 2)

The method of claim 2, wherein the osteoarthritis cartilage synthesis marker is PIIANP.

### Claim 6 (depends on 2)

The method of claim 2, wherein the osteoarthritis cartilage degradation marker is selected from the group consisting of CTX-II, Type II collagen, Type VI collagen, COMP, keratin sulfate, link protein, aggrecan, and aggrecan fragments.

### Claim 7 (depends on 2)

The method of claim 2, wherein the detection of step (a) is performed by an assay selected from the group consisting of radioimmunoassays, enzyme immunoassays, ligand assays, immunoradiometric assays, fluoroimmunoassays, and enzyme-linked immunosorbent assays.

### Claim 8 (depends on 7)

The method of claim 7, wherein the enzyme-linked immunosorbent assay is selected from the group consisting of competitive ELISAs and sandwich ELISAs.

### Claim 9 (depends on 2)

The method of claim 2, wherein the biological sample is selected from the group consisting of blood, serum, urine, sputum, interstitial fluid, joint debris, cartilage fragments and synovial cells.

### Claim 10 (depends on 2)

The method of claim 2, wherein the subject is a mammal.

### Claim 11 (depends on 10)

The method of claim 10, wherein the mammal is a human.

### Claim 12 (depends on 2)

The method of claim 2, wherein the biological sample is cartilage.

### Claim 13 (depends on 12)

The method of claim 12, wherein the cartilage is knee cartilage.

### Claim 14

A method for determining the progress of osteoarthritis or cartilage destruction in a subject, said method comprising quantifying an uncoupling of type II collagen synthesis from type II collagen degradation in the subject.

### Claim 15 (depends on 14)

A method in accordance with claim 14 wherein quantifying an uncoupling of type II collagen synthesis from type II collagen degradation in the subject comprises:
(a) measuring an amount of a synthesis marker in a biological sample of the subject;
(b) measuring an amount of a degradation marker in the biological sample of the subject;
(c) calculating a value of an uncoupling index using the amount of synthesis marker and the amount of degradation marker;
(d) comparing the value of the uncoupling index with predetermined standards to quantify the status of osteoarthritis or cartilage destruction in the subject.

### Claim 16 (depends on 15)

A method in accordance with claim 15, wherein step (a) and step (b) are performed by an assay selected from the group consisting of radioimmunoassays, enzyme immunoassays, ligand assays, immunoradiometric assays, fluoroimmunoassays, and enzyme-linked immunosorbent assays.

### Claim 17 (depends on 16)

A method in accordance with claim 16, wherein the enzyme-linked immunosorbent assay is selected from the group consisting of competitive ELISAs and sandwich ELISAs.

### Claim 18 (depends on 15)

The method of claim 15, wherein said sample is selected from the group consisting of blood, serum, urine, sputum, interstitial fluid, joint debris, cartilage fragments and synovial cells.

### Claim 19 (depends on 15)

The method of claim 15, wherein the osteoarthrits cartilage synthesis marker is PIIANP.

### Claim 20 (depends on 15)

The method of claim 15, wherein the osteoarthrits cartilage degradation marker is selected from the group consisting of CTX-II, Type II collagen, Type VI collagen, COMP, keratin sulfate, link protein, aggrecan, and aggrecan fragments.

### Claim 21

A method for detecting or predicting osteoarthritis in a subject, the method comprising the steps of:
(a) providing a first and a second body fluid sample, wherein the first sample is taken from a subject from which status of osteoarthritis is to be determined and the second sample is taken from the same subject at a later time;
(b) providing a first antibody, second antibody, third labeled antibody, and fourth labeled antibody, wherein the first antibody is capable of specifically binding to a human collagen synthesis marker, the second antibody is capable of specifically binding to a human collagen degradation marker, the third labeled antibody is capable of binding to the human collagen synthesis marker, and the fourth labeled antibody is capable of binding to the human collagen degradation marker, and a detecting reagent capable of detecting the label;
(c) contacting the first antibody, second antibody, third labeled antibody, fourth labeled antibody, and the detecting reagent with the first body fluid sample;
(d) contacting the first antibody, second antibody, third labeled antibody, fourth labeled antibody, and the detecting reagent with the second body fluid sample; and,
(e) detecting the amount of and determining the concentration of human collagen synthesis marker and collagen degradation marker in the first sample to provide a reference value and detecting the amount of and determining the concentration of human collagen synthesis marker and collagen degradation marker in the second sample, wherein an increased concentration of human collagen degradation marker coupled with a decreased concentration of collagen synthesis marker in the second sample compared to the reference value indicates that the test subject has a high probability of having had or being at risk of progressive osteoarthritis.

### Claim 22 (depends on 21)

The method of claim 21, wherein the concentration of human collagen degradation marker and synthesis marker in both the first and second body fluid samples from the subject is determined by an immunological assay.

### Claim 23 (depends on 22)

The method of claim 22, wherein the immunological assay is selected from the group consisting of radioimmunoassays, enzyme immunoassays, ligand assays, immunoradiometric assays, fluoroimmunoassays, and enzyme-linked immunosorbent assays.

### Claim 24 (depends on 23)

The method of claim 23, wherein the enzyme-linked immunosorbent assay is selected from the group consisting of competitive ELISAs and sandwich ELISAs.

### Claim 25 (depends on 21)

The method of claim 21, wherein the body fluid sample of step (a) is selected from the group consisting of blood, serum, urine, sputum, interstitial fluid, joint debris, cartilage fragments and synovial cells.

### Claim 26 (depends on 21)

The method of claim 21, wherein the first antibody and second antibody is immobilized on a solid surface.

### Claim 27 (depends on 21)

The method of claim 21, wherein in step (b), the label of the third and fourth labeled antibodies comprise biotin, and the third and fourth antibodies are detected by the method further providing a composition conjugated to streptavidin and adding the composition to the contacted first antibody or second antibody, third labeled antibody, and fourth labeled antibody of step (d), wherein the composition is directly detectable or the composition generates a second directly detectable composition.

### Claim 28 (depends on 27)

The method of claim 27, wherein the detectable composition is an enzyme.

### Claim 29 (depends on 28)

The method of claim 28, wherein the enzyme is a horseradish peroxidase.

### Claim 30 (depends on 28)

The method of claim 28, wherein the enzyme generates a detectable colored composition.

### Claim 31 (depends on 21)

The method of claim 21, wherein the first antibody or the second antibody is a monoclonal antibody.

### Claim 32 (depends on 21)

The method of claim 21, wherein the first antibody or the second antibody is a polyclonal antibody.

### Claim 33 (depends on 21)

The method of claim 21, wherein the first antibody is a monoclonal antibody and the second antibody is a polyclonal antibody.

### Claim 34 (depends on 21)

The method of claim 21, wherein the osteoarthrits cartilage synthesis marker is PIIANP.

### Claim 35 (depends on 21)

The method of claim 21, wherein the osteoarthritis cartilage degradation marker is selected from the group consisting of CTX-II, Type II collagen, Type VI collagen, COMP, keratin sulfate, link protein, aggrecan, and aggrecan fragments.

### Claim 36

A method for detecting or predicting osteoarthritis in a subject, the method comprising the steps of:
(a) providing a body fluid sample, wherein the sample is taken from a subject from which status of osteoarthritis is to be determined;
(b) providing a first antibody, second antibody and a third labeled antibody, wherein the first antibody is capable of specifically binding to a human collagen synthesis marker, the second antibody is capable of specifically binding to a human collagen degradation marker, and the third labeled antibody is capable of binding to both the human collagen synthesis marker and human collagen degradation marker, and a detecting reagent capable of detecting the label;
(c) contacting the first antibody, second antibody, and the third labeled antibody, and the detecting reagent with the body fluid sample;
(d) contacting the first antibody, second antibody and the third labeled antibody, and the detecting reagent with the body fluid sample; and,
(e) detecting the amount of and determining the concentration of human collagen synthesis marker and collagen degradation marker in the sample, wherein a concentration of human collagen degradation marker greater than one standard deviation above a predetermined reference value uncoupled with a decreased concentration of collagen synthesis marker less than one standard deviation below a predetermined reference value indicates that the test subject has a high probability of having had or being at risk of progressive osteoarthritis.

### Claim 37 (depends on 36)

The method of claim 36, wherein the concentration of human collagen degradation marker and synthesis marker in the body fluid sample from the subject is determined by an immunological assay.

### Claim 38 (depends on 37)

The method of claim 37, wherein the immunological assay is selected from the group consisting of radioimmunoassays, enzyme immunoassays, ligand assays, immunoradiometric assays, fluoroimmunoassays, and enzyme-linked immunosorbent assays.

### Claim 39 (depends on 38)

The method of claim 38, wherein the enzyme-linked immunosorbent assay is selected from the group consisting of competitive ELISAs and sandwich ELISAs.

### Claim 40 (depends on 36)

The method of claim 36, wherein the body fluid sample of step (a) is selected from the group consisting of blood, serum, urine, sputum, interstitial fluid, joint debris, cartilage fragments and synovial cells.

### Claim 41 (depends on 36)

The method of claim 36, wherein the osteoarthrits cartilage synthesis marker is PIIANP.

### Claim 42 (depends on 36)

The method of claim 36, wherein the osteoarthrits cartilage degradation marker is selected from the group consisting of CTX-II, Type II collagen, Type VI collagen, COMP, keratin sulfate, link protein, aggrecan, and aggrecan fragments.

### Claim 43

A solid support in contact with a combination of a first antibody and second antibody, wherein the first antibody is capable of specifically binding to a human collagen synthesis marker and the second antibody is capable of specifically binding to a human collagen degradation marker.

### Claim 44 (depends on 43)

The solid support of claim 43, wherein the osteoarthritis cartilage synthesis marker is PIIANP.

### Claim 45 (depends on 43)

The solid support of claim 43, wherein the osteoarthritis cartilage degradation marker is selected from the group consisting of CTX-II, Type II collagen, Type VI collagen, COMP, keratin sulfate, link protein, aggrecan, and aggrecan fragments.

### Claim 46

A kit for detecting the progression of osteoarthritis comprising instructions setting forth a method comprising the following:
(a) providing a first and a second body fluid sample, wherein the first sample is taken from a subject from which status of osteoarthritis is to be determined and the second sample is taken from the same subject at a later time; and
(b) detecting the amount of and determining the concentration of human collagen synthesis marker and collagen degradation marker in the first sample to provide a reference value, and detecting the amount of and determining the concentration of human collagen synthesis marker and collagen degradation marker in the second sample, wherein an increased concentration of human collagen degradation marker coupled with a decreased concentration of collagen synthesis marker in the second sample compared to the reference value indicates that the test subject has a high probability of having had or being at risk of progressive osteoarthritis.
